Pubblicazioni

Il test prognostico per il tumore al seno EndoPredict è stato oggetto di molte pubblicazioni in una serie di riviste di alto profilo, tutte disponibili e ordinate per anno nella nostra libreria delle pubblicazioni, di seguito.

Elenco delle pubblicazioni

Ordinate per anno, dalle più recenti

Anno Autore Titolo Rivista Link
2022 Jank, Paul et al. Comparison of risk assessment in 1652 early ER positive, HER2 negative breast cancer in a real-world data set: classical pathological parameters vs. 12-gene molecular assay (EndoPredict). Breast Cancer Research And Treatment Ulteriori informazioni
2021 Vázquez-Juarez, Daniela et al. Follow-up of prospective cohort of Mexican premenopausal women with breast cancer who received guided adjuvant treatment with the EndoPredict assay. SABCS 2021 Ulteriori informazioni
2021 Penault-LLorca, Frederique et al. Prognostic value of EndoPredict test in patients screened for UNIRAD, a UCBG randomized, double blind, phase III international trial evaluating the addition of *** (EVE) to adjuvant hormone therapy (HT) in women with high risk HR+, HER2- early breast cancer (eBC). SABCS 2021 Ulteriori informazioni
2021 Constantinidou, Anastasia et al. Clinical Validation Of Endopredict In Premenopausal Women With Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor 2-Negative (HER2-) Primary Breast Cancer. ASCO 2021 Ulteriori informazioni
2021 Lehmann-Che, Jacqueline et al. SiMoSein, A Real-Life Prospective Evaluation Of Endopredict Use In Early ER-Positive, HER2-Negative Breast Cancers. Annals Of Oncology Ulteriori informazioni
2021 Dinh, Phuong et al. Impact Of The Endopredict Genomic Assay On Treatment Decisions For Oestrogen Receptor-Positive Early Breast Cancer Patients: Benefits Of Physician Selective Testing. Breast Cancer Research And Treatment Ulteriori informazioni
2020 Villarreal-Garza, Cynthia et al. Change In Therapeutic Management After The Endopredict Assay In A Prospective Decision Impact Study Of Mexican Premenopausal Breast Cancer Patients. PLOS ONE Ulteriori informazioni
2020 Somashekhar SP et al. Individualized chemotherapy benefit prediction by EndoPredict in patients with early breast cancer in an Indian cohort. Journal of Clinical Oncology Global Oncology Ulteriori informazioni
2020 Dubsky, Peter et al. The EndoPredict score predicts response to neoadjuvant chemotherapy and neoendocrine therapy in hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer patients from the ABCSG-34 trial. European Journal of Cancer Ulteriori informazioni
2020 Almstedt, K et al. EndoPredict in early hormone receptor-positive, HER2-negative breast cancer. Breast Cancer Res Treat. Ulteriori informazioni
2020 Jahn SW et al. Clinically high-risk breast cancer displays markedly discordant molecular risk predictions between the MammaPrint and EndoPredict tests. Br J Cancer Ulteriori informazioni
2020 Neusser S et al. Retrospective cost-analysis of the EndoPredict test in patients with primary breast cancer in a German breast center. Journal of Public Health: From Theory to Practice 2020 Ulteriori informazioni
2020 Soliman H et al. Evaluation of the 12-Gene molecular score and the 21-gene recurrence score as predictors of response to neo-adjuvant chemotherapy in estrogen receptor-positive, HER2-negative breast cancer. Annals of Surgical Oncology Ulteriori informazioni
2020 Penault-Llorca, Frederique et al. Decision of adjuvant chemotherapy in intermediate risk luminal breast cancer patients: A prospective multicenter trial assessing the clinical and psychological impact of EndoPredict® (EPclin) use (UCBG 2-14). Breast Ulteriori informazioni
2020 Noske A et al. Risk stratification in luminal-type breast cancer: Comparison of Ki-67 with EndoPredict test results. Breast Ulteriori informazioni
2019 Filipits, Martin et al. Prediction Of Distant Recurrence Using Endopredict Among Women With ER+, HER2− Node-Positive And Node-Negative Breast Cancer Treated With Endocrine Therapy Only. Clinical Cancer Research Ulteriori informazioni
2019 Soliman H et al. Predicting Expected Absolute Chemotherapy Treatment Benefit in Women With Early-Stage Breast Cancer Using EndoPredict, an Integrated 12-Gene Clinicomolecular Assay. JCO Precis Oncol Ulteriori informazioni
2019 Hannouf MB et al. Cost-effectiveness analysis of multigene expression profiling assays to guide adjuvant therapy decisions in women with invasive early-stage breast cancer. Pharmacogenomics J. Ulteriori informazioni
2019 Thangaraiah F et al. The impact of EndoPredict® on decision making with increasing oncological work experience: can overtreatment be avoided? Arch Gynecol Obstet. Ulteriori informazioni
2019 Sestak, Ivana et al. Prediction Of Chemotherapy Benefit By Endopredict In Patients With Breast Cancer Who Received Adjuvant Endocrine Therapy Plus Chemotherapy Or Endocrine Therapy Alone. Breast Cancer Research And Treatment Ulteriori informazioni
2018 Fallowfield, Lesley et al. Enhancing Decision-Making About Adjuvant Chemotherapy In Early Breast Cancer Following Endopredict Testing. Psycho-Oncology Ulteriori informazioni
2018 Sestak, Ivana et al. Comparison Of The Performance Of 6 Prognostic Signatures For Estrogen Receptor–Positive Breast Cancer. JAMA Oncology Ulteriori informazioni
2018 Lacroix-Triki M et al. EndoPredict prognostic signature in pN1mi, estrogen receptor-positive breast cancer: analysis of the French national registry for molecular signatures. Poster: SABCS 2018 Ulteriori informazioni
2018 Ettl, Johannes et al. RESCUE: REACHING FOR EVIDENCE-BASED CHEMOTHERAPY USE IN ENDOCRINE SENSITIVE BREAST CANCER, A prospective health care study on risk assessment by the clinicomolecular test EndoPredict® and long-term patient outcome in early luminal breast cancer. Poster: SABCS 2018 Ulteriori informazioni
2018 Ettl, Johannes et al. First prospective outcome data for the clinico-molecular test EndoPredict® in hormone receptor positive, HER2-negative early breast cancer in clinical routine. Poster: SABCS 2018 Ulteriori informazioni
2018 Mokbel K et al. The impact of EndoPredict clinical score on chemotherapy recommendations in women with invasive ER+/HER2- breast cancer stratified as having moderate or poor prognosis by Nottingham Prognostic Index. Anticancer Res. Ulteriori informazioni
2018 Loibl S et al. Risk assessment after neoadjuvant chemotherapy in luminal breast cancer using a clinicomolecular predictor. Clin Cancer Res. Ulteriori informazioni
2018 Gradishar W et al. Predicting expected absolute chemotherapy treatment benefit in women with early-stage breast cancer using a 12-gene expression assay. J Clin Oncol Ulteriori informazioni
2018 Lehmann-Che, Jacqueline et al. First French pilot quality assessment of the EndoPredict test for early luminal breast carcinoma. Anticancer Res. Ulteriori informazioni
2018 Mokbel K et al. A comparison of the performance of EndoPredict clinical and NHS PREDICT in 120 patients treated for ER-positive breast cancer. Anticancer Res. Ulteriori informazioni
2018 Chow LWC et al. Neoadjuvant palbociclib on ER+ breast cancer (N007): clinical response and EndoPredict’s value. Endocr Relat Cancer. Ulteriori informazioni
2017 Pan, Hongchao et al. 20-Year Risks Of Breast-Cancer Recurrence After Stopping Endocrine Therapy At 5 Years. New England Journal Of Medicine Ulteriori informazioni
2017 Ettl, Johannes et al. Decision impact and feasibility of different ASCO-recommended biomarkers in early breast cancer: Prospective comparison of molecular marker EndoPredict and protein marker uPA/PAI-1. PLoS One Ulteriori informazioni
2017 Peláez-García A et al. Comparison of risk classification between EndoPredict and MammaPrint in ER-positive/HER2-negative primary invasive breast cancer. PLoS One Ulteriori informazioni
2017 Bösl A et al. MammaPrint versus EndoPredict: Poor correlation in disease recurrence risk classification of hormone receptor positive breast cancer. PLoS One Ulteriori informazioni
2017 Warf MB et al. Analytical validation of a 12-gene molecular test for the prediction of distant recurrence in breast cancer. Future Sci OA Ulteriori informazioni
2016 Penault-Llorca, Frederique et al. UCBG 2-14: A prospective multicenter non-randomized trial evaluating the effect of EndoPredict® (EPclin®) clinicogenomic test on treatment decision making among patients with intermediate clinical risk. Poster: SABCS 2016 Ulteriori informazioni
2016 Martin M et al. Prognostic ability of EndoPredict compared to research-based versions of the PAM50 risk of recurrence (ROR) scores in node-positive, estrogen receptor-positive, and HER2-negative breast cancer. A GEICAM/9906 sub-study. Breast Cancer Res Treat. Ulteriori informazioni
2016 Buus, Richard et al. Comparison Of Endopredict And Epclin With Oncotype DX Recurrence Score For Prediction Of Risk Of Distant Recurrence After Endocrine Therapy. Journal Of The National Cancer Institute Ulteriori informazioni
2015 Fitzal F et al. The genomic expression test EndoPredict is a prognostic tool for identifying risk of local recurrence in postmenopausal endocrine receptorpositive, her2neu-negative breast cancer patients randomised within the prospective ABCSG 8 trial. Br J Cancer Ulteriori informazioni
2015 Blank PR et al. Cost-effectiveness analysis of prognostic gene expression signature-based stratification of early breast cancer patients. Pharmacoeconomics Ulteriori informazioni
2014 Martin, Miguel et al. Clinical Validation Of The Endopredict Test In Node-Positive, Chemotherapy-Treated ER+/HER2− Breast Cancer Patients: Results From The GEICAM 9906 Trial. Breast Cancer Research Ulteriori informazioni
2014 Bertucci F et al. EndoPredict predicts for the response to neoadjuvant chemotherapy in ER-positive, HER2-negative breast cancer. Cancer Lett. Ulteriori informazioni
2014 Poremba C et al. Preanalytical variables and performance of diagnostic RNA-based gene expression analysis in breast cancer. Virchows Arch. Ulteriori informazioni
2013 Müller, Berit Maria et al. The Endopredict Gene-Expression Assay In Clinical Practice – Performance And Impact On Clinical Decisions. Plos ONE Ulteriori informazioni
2013 Brase JC et al. From high-throughput microarray-based screening to clinical application: the development of a second generation multigene test for breast cancer prognosis. Microarrays Ulteriori informazioni
2013 Varga Z et al. Comparison of EndoPredict and Oncotype DX test results in hormone receptor positive invasive breast cancer. PLoS One Ulteriori informazioni
2013 Dubsky, Peter et al. Endopredict Improves The Prognostic Classification Derived From Common Clinical Guidelines In ER-Positive, HER2-Negative Early Breast Cancer. Annals Of Oncology Ulteriori informazioni
2013 Dubsky, Peter et al. The Endopredict Score Provides Prognostic Information On Late Distant Metastases In ER+/HER2− Breast Cancer Patients. British Journal Of Cancer Ulteriori informazioni
2012 Denkert, Carsten et al. Decentral Gene Expression Analysis For ER+/Her2− Breast Cancer: Results Of A Proficiency Testing Program For The Endopredict Assay. Virchows Archiv Ulteriori informazioni
2012 Kronenwett R et al. Decentral gene expression analysis: analytical validation of the EndoPredict genomic multianalyte breast cancer prognosis test. BMC Cancer Ulteriori informazioni
2012 Müller BM et al. Comparison of the RNA-based EndoPredict multigene test between core biopsies and corresponding surgical breast cancer sections. J Clin Pathol. Ulteriori informazioni
2011 Filipits, Martin et al. A New Molecular Predictor Of Distant Recurrence In ER-Positive, HER2-Negative Breast Cancer Adds Independent Information To Conventional Clinical Risk Factors. Clinical Cancer Research Ulteriori informazioni
2011 Müller BM et al. Quantitative determination of estrogen receptor, progesterone receptor, and HER2 mRNA in formalin-fixed paraffin-embedded tissue–a new option for predictive biomarker assessment in breast cancer. Diagn Mol Pathol. Ulteriori informazioni
2009 Simon, Richard et al. Use Of Archived Specimens In Evaluation Of Prognostic And Predictive Biomarkers. Journal Of The National Cancer Institute Ulteriori informazioni